2Kopetz VA, PennoM A, Hoffmann P, et al. Potential mecha- nisms of the acute coronary syndrome presentation in patients with the coronary slow flow phenomenon insight from a plas- ma proteomic approach[J]. Int J Cardiol ,2012,156( 1 ) :84 -91. 被引量：1
3Wozakowska - Kaplon B, Niedziela J, Krzyzak P, et al. Clini- cal manifestations of slow corona y flow from acute coronary syndrome to serious arrhythmia[J].Cardiol J,2009,16 (5) : 462 - 468. 被引量：1
5Numasawa Y, Kohsaka S, Miyata H,et al.Use of thrombol- ysis in myocardial infarction risk score to predict bleeding complications in patients with unstable angina and non- ST elevation myocardial infarction undergoing percuta- neous coronary intervention[J].Cardiovasc Interv Ther,2013, 28(3):242-249. 被引量：1
6Wang JN,Diao S,Tang YJ,et al.Intracoronary versus in- travenous administration of abciximab in patients with a- cute coronary syndrome: a meta-analysis [J].PLoS One, 2013,8(2) : e58077. 被引量：1
7Mrdovic I,Savic L,Krljanac G,et al.Simple risk algo- rithm to predict serious bleeding in patients with ST- segment elevation myocardial infarction undergoing pri- mary pereutaneous coronary intervention: RISK-PCI bleeding score[J].Cire J,2013,77(7): 1719-1727. 被引量：1
8Nikus K.12-lead electrocardiogram in acute coronary syndrome:association with coronary angiography findings and outcome[M].Tampere ;Tampere University Press, 2012. 被引量：1
9DIAZ JF,CARDENAL R,GOMEZ-MANCHERO A,et al.Safety and efficacy of tirofiban as adjunctive therapy for patients with ST-elevation myocardial infarction:a comparison versus placebo and abciximab[J].Cardiovasc Hematol Agents Med Chem,2011,9(3):147-153. 被引量：1
10GEERTS WH,BERGQVIST D,PINEO GF,et al.Prevention of venous thromboembolism:American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)[J].Chest,2008,133(6):381-453. 被引量：1
